This Is MS Multiple Sclerosis Knowledge & Support Community

Posted: **Wed Aug 12, 2009 8:02 pm**

I finally moved daclizumab from phase 2 to phase 3 based on the post from Frank a few days ago. It's still in a phase 2 trial, but I figured I just move it into phase 3.

Posted: **Fri Aug 28, 2009 2:32 pm**

Is there anything else you can share on this study - I am being considered as a canidate as I type and am cautiously optomistic!

Posted: **Fri Aug 28, 2009 4:36 pm**

Sorry, I don't really know any more. All I've seen are the news articles, based on this press release:

http://investors.facetbiotech.com/phoen ... highlight=

Posted: **Fri Aug 28, 2009 4:45 pm**

I moved PI-2301 from phase 1 to phase 2, based on THIS post from scorpion.

Posted: **Mon Sep 14, 2009 7:27 am**

I updated the list (and the progressive list) based on scorpion's post:
http://www.thisisms.com/ftopict-8150.html

Posted: **Mon Sep 28, 2009 7:56 am**

I removed Atacicept (aka TACI-Ig) (Merck Serono and ZymoGenetics) from the phase 2 list based on this post from scorpion:
http://www.thisisms.com/ftopicp-69164.html#69164

Posted: **Fri Oct 09, 2009 3:57 pm**

I moved "R3477 (aka ACT-128800) (Roche / Actelion)" from phase 1 to phase 2, based on this post from scorpion:
http://www.thisisms.com/ftopicp-70568.html#70568

Posted: **Sun Nov 22, 2009 11:56 am**

I removed BCX-4208 from the phase 1 list because there is no indication that they are testing on MS patients right now and it is being tested on people with gout, which suggests to me it won’t be helpful in MS, since low uric acid is seen in some MS patients, whereas gout is a problem with high uric acid levels.

http://investor.shareholder.com/biocrys ... eID=332229

http://tinyurl.com/y9vb8d3

Posted: **Tue Nov 24, 2009 9:05 pm**

I moved BGC20-0134 (BTG) from phase 1 to phase 2, based on the page on BTG's website:
http://www.btgplc.com/BTGPipeline/233/BGC200134.html

It's a good day.

Posted: **Sun Nov 29, 2009 5:11 pm**

I just took a hatchet to the phase 1 list. If anybody wants the gory details, they are here: http://mspipeline.wordpress.com/category/updates/

Posted: **Wed Jan 20, 2010 9:43 pm**

I added AIN457 (Novartis) to the phase 2 list based on this clinicaltrials.gov entry:

http://www.clinicaltrials.gov/ct2/show/NCT01051817

Posted: **Wed Jan 27, 2010 8:36 am**

I added BIIB033 (Anti-Lingo) to the phase 1 list based on a post from ElMarino. The post cites a Dow Jones article. The trial is also now listed in clinicaltrials.gov

http://english.capital.gr/news.asp?id=896271

http://www.clinicaltrials.gov/ct2/show/NCT01052506

Posted: **Mon Apr 05, 2010 8:33 pm**

dignan wrote:Another one for pre-clinical - LLDT-8. The thing I'm happy to see here is that this research comes from China. I'd love to see the MS research world harness some more of the immense brain-power in China and India.

(5R)-5-Hydroxytriptolide (LLDT-8 ), a novel triptolide derivative, prevents experimental autoimmune encephalomyelitis via inhibiting T cell activation.

J Neuroimmunol. 2006 May 17; [Epub ahead of print]
Fu YF, Zhu YN, Ni J, Zhong XG, Tang W, Zhou R, Zhou Y, Dong JR, He PL, Wan H, Li YC, Yang YF, Zuo JP.
Laboratories of Immunopharmacology and Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China.

A novel triptolide derivative (5R)-5-hydroxytriptolide (LLDT-8 ) has been shown to have potent immunosuppressive activities. Here LLDT-8 was evaluated in experimental autoimmune encephalomyelitis (EAE), the model of multiple sclerosis (MS).

LLDT-8 reduced the incidence and severity of EAE, which was associated with the inhibition of the MOG 35-55 lymphocyte recall response, anti-MOG 35-55 T cell responses, interleukin (IL)-2 and interferon (IFN)-gamma production. In vitro, LLDT-8 inhibited primary T cells proliferation, division, IL-2 and IFN-gamma production stimulated with anti-CD3/28.

These findings highlight the fact that LLDT-8 prevents EAE by suppressing T cell proliferation and activation, with a potential for treatment of MS.

<shortened url>

Man, I really wish someone would pursue the Triptolide angle. A naturally occurring compound that targets the ever mentioned IL-2. I'd be tempted to order it from China but it is highly toxic as evidenced by its comically horrifying nicknames: "Walk Seven Steps and Die Vine" and "Intestine Breaking Plant"

Posted: **Wed Apr 14, 2010 2:39 pm**

Rainer, yeah, I don't like the sounds of those nicknames. I'm happy to wait for some pharmaceutical derivative that would be safer. Maybe, "walk seven steps and stop for a little rest".

Posted: **Sun Jul 25, 2010 2:42 pm**

Just read it all, and to everyone, AWSOME, just Awsome!

This Is MS Multiple Sclerosis Knowledge & Support Community

Summary of the pipeline

HALT MS